NYSE:LCI

Lannett Competitors

$4.95
-0.08 (-1.59 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.87
Now: $4.95
$5.12
50-Day Range
$5.03
MA: $6.10
$7.14
52-Week Range
$4.87
Now: $4.95
$10.70
Volume584,267 shs
Average Volume593,066 shs
Market Capitalization$204.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31

Competitors

Lannett (NYSE:LCI) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying LCI stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Lannett, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Lannett (NYSE:LCI) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Insider & Institutional Ownership

86.1% of Lannett shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 13.6% of Lannett shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Lannett and Johnson & Johnson, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lannett03002.00
Johnson & Johnson031102.79

Lannett currently has a consensus target price of $8.50, suggesting a potential upside of 71.72%. Johnson & Johnson has a consensus target price of $180.6429, suggesting a potential upside of 12.03%. Given Lannett's higher possible upside, research analysts clearly believe Lannett is more favorable than Johnson & Johnson.

Volatility & Risk

Lannett has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Lannett and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lannett-5.09%12.62%3.39%
Johnson & Johnson21.01%34.64%13.40%

Earnings and Valuation

This table compares Lannett and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lannett$545.74 million0.38$-33,370,000.00$1.074.63
Johnson & Johnson$82.06 billion5.17$15.12 billion$8.6818.58

Johnson & Johnson has higher revenue and earnings than Lannett. Lannett is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Lannett on 10 of the 14 factors compared between the two stocks.

Lannett (NYSE:LCI) and Pfizer (NYSE:PFE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Volatility & Risk

Lannett has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Lannett and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lannett-5.09%12.62%3.39%
Pfizer17.85%24.88%9.32%

Insider & Institutional Ownership

86.1% of Lannett shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 13.6% of Lannett shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Lannett and Pfizer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lannett03002.00
Pfizer010302.23

Lannett currently has a consensus target price of $8.50, suggesting a potential upside of 71.72%. Pfizer has a consensus target price of $38.5714, suggesting a potential upside of 5.39%. Given Lannett's higher possible upside, research analysts clearly believe Lannett is more favorable than Pfizer.

Earnings and Valuation

This table compares Lannett and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lannett$545.74 million0.38$-33,370,000.00$1.074.63
Pfizer$51.75 billion3.94$16.27 billion$2.9512.41

Pfizer has higher revenue and earnings than Lannett. Lannett is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Lannett on 10 of the 14 factors compared between the two stocks.

Lannett (NYSE:LCI) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Risk and Volatility

Lannett has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Profitability

This table compares Lannett and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lannett-5.09%12.62%3.39%
Merck & Co., Inc.24.33%53.83%16.83%

Insider and Institutional Ownership

86.1% of Lannett shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 13.6% of Lannett shares are owned by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Lannett and Merck & Co., Inc., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lannett03002.00
Merck & Co., Inc.021202.86

Lannett currently has a consensus target price of $8.50, suggesting a potential upside of 71.72%. Merck & Co., Inc. has a consensus target price of $95.9167, suggesting a potential upside of 25.69%. Given Lannett's higher possible upside, equities analysts plainly believe Lannett is more favorable than Merck & Co., Inc..

Earnings & Valuation

This table compares Lannett and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lannett$545.74 million0.38$-33,370,000.00$1.074.63
Merck & Co., Inc.$46.84 billion4.12$9.84 billion$5.1914.70

Merck & Co., Inc. has higher revenue and earnings than Lannett. Lannett is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Lannett on 10 of the 14 factors compared between the two stocks.

Lannett (NYSE:LCI) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Risk and Volatility

Lannett has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Profitability

This table compares Lannett and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lannett-5.09%12.62%3.39%
AbbVie18.16%439.24%13.22%

Insider and Institutional Ownership

86.1% of Lannett shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 13.6% of Lannett shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Lannett and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lannett03002.00
AbbVie121402.76

Lannett currently has a consensus target price of $8.50, suggesting a potential upside of 71.72%. AbbVie has a consensus target price of $115.75, suggesting a potential upside of 7.63%. Given Lannett's higher possible upside, equities analysts plainly believe Lannett is more favorable than AbbVie.

Earnings & Valuation

This table compares Lannett and AbbVie's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lannett$545.74 million0.38$-33,370,000.00$1.074.63
AbbVie$33.27 billion5.71$7.88 billion$8.9412.03

AbbVie has higher revenue and earnings than Lannett. Lannett is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Lannett on 10 of the 14 factors compared between the two stocks.

Lannett (NYSE:LCI) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Risk and Volatility

Lannett has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Profitability

This table compares Lannett and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lannett-5.09%12.62%3.39%
Eli Lilly and24.01%166.45%15.18%

Insider and Institutional Ownership

86.1% of Lannett shares are owned by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are owned by institutional investors. 13.6% of Lannett shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Lannett and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lannett03002.00
Eli Lilly and041102.73

Lannett currently has a consensus target price of $8.50, suggesting a potential upside of 71.72%. Eli Lilly and has a consensus target price of $196.40, suggesting a potential upside of 6.46%. Given Lannett's higher possible upside, equities analysts plainly believe Lannett is more favorable than Eli Lilly and.

Earnings & Valuation

This table compares Lannett and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lannett$545.74 million0.38$-33,370,000.00$1.074.63
Eli Lilly and$22.32 billion7.93$8.32 billion$6.0430.54

Eli Lilly and has higher revenue and earnings than Lannett. Lannett is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly and beats Lannett on 10 of the 14 factors compared between the two stocks.

Lannett (NYSE:LCI) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Risk and Volatility

Lannett has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares Lannett and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lannett-5.09%12.62%3.39%
Bristol-Myers Squibb-0.11%27.48%10.77%

Insider and Institutional Ownership

86.1% of Lannett shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 13.6% of Lannett shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Lannett and Bristol-Myers Squibb, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lannett03002.00
Bristol-Myers Squibb031012.86

Lannett currently has a consensus target price of $8.50, suggesting a potential upside of 71.72%. Bristol-Myers Squibb has a consensus target price of $74.6429, suggesting a potential upside of 19.22%. Given Lannett's higher possible upside, equities analysts plainly believe Lannett is more favorable than Bristol-Myers Squibb.

Earnings & Valuation

This table compares Lannett and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lannett$545.74 million0.38$-33,370,000.00$1.074.63
Bristol-Myers Squibb$26.15 billion5.35$3.44 billion$4.6913.35

Bristol-Myers Squibb has higher revenue and earnings than Lannett. Lannett is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Lannett on 10 of the 15 factors compared between the two stocks.


Lannett Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.25-1.1%$424.52 billion$82.06 billion25.35
Pfizer logo
PFE
Pfizer
2.3$36.60-1.7%$204.14 billion$51.75 billion23.61Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.31-1.1%$193.09 billion$46.84 billion16.88News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.54-1.3%$189.79 billion$33.27 billion22.74Analyst Report
Eli Lilly and logo
LLY
Eli Lilly and
2.1$184.49-1.0%$176.92 billion$22.32 billion30.15
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.61-1.1%$139.87 billion$26.15 billion-569.13Analyst Upgrade
Zoetis logo
ZTS
Zoetis
2.2$159.85-0.1%$75.93 billion$6.26 billion47.43
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.31-0.9%$25.69 billionN/A0.00Analyst Revision
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.48-0.5%$20.50 billion$1.30 billion24.99Analyst Upgrade
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40-0.3%$9.09 billion$2.16 billion50.91Insider Selling
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.96-12.7%$373.27 million$16.54 million-3.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.55-2.8%$358.06 million$111.39 million25.36News Coverage
Gap Down
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.36-0.5%$166.75 million$15.96 million-2.64Unusual Options Activity
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.17-4.1%$47.30 million$47.53 million-14.41News Coverage
Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.